List of Excipients in Branded Drug THALITONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Casper Pharma LLC	THALITONE	chlorthalidone	70199-017	CELLULOSE, MICROCRYSTALLINE
Casper Pharma LLC	THALITONE	chlorthalidone	70199-017	LACTOSE MONOHYDRATE
Casper Pharma LLC	THALITONE	chlorthalidone	70199-017	MAGNESIUM STEARATE
Casper Pharma LLC	THALITONE	chlorthalidone	70199-017	POVIDONE
Casper Pharma LLC	THALITONE	chlorthalidone	70199-017	SILICON DIOXIDE
Casper Pharma LLC	THALITONE	chlorthalidone	70199-017	SODIUM STARCH GLYCOLATE TYPE A POTATO

THALITONE Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: September 16, 2026

THALITONE is a chlorthalidone tablet brand used for hypertension and edema. Its commercial opportunity does not depend on active-ingredient exclusivity. Chlorthalidone is an established, off-patent diuretic, so value is concentrated in dose flexibility, tablet quality, supply reliability, tolerability, regulatory execution and payer access. The strongest formulation opportunity is a robust low-dose tablet platform that delivers accurate content uniformity at 15 mg while supporting 25 mg and 50 mg presentations.

What is THALITONE and how is it positioned commercially?

THALITONE contains chlorthalidone, a thiazide-like diuretic with a long duration of action. U.S. labeling identifies 15 mg, 25 mg and 50 mg tablet strengths. The product is used primarily for hypertension and fluid-retention indications described in its FDA labeling. [1]

Attribute	THALITONE
Active ingredient	Chlorthalidone
Dosage form	Immediate-release oral tablet
Primary therapeutic category	Antihypertensive and diuretic
Market status	Established prescription product
Key dose strengths	15 mg, 25 mg and 50 mg
Competitive substitutes	Generic chlorthalidone, hydrochlorothiazide, indapamide and loop diuretics in selected patients
Main differentiation	Brand identity, availability of a 15 mg strength, supply consistency and prescribing familiarity
Biologic risk	None
Biosimilar risk	None

Chlorthalidone has a longer pharmacologic effect than hydrochlorothiazide. That characteristic supports once-daily dosing but also increases the commercial importance of dose precision and electrolyte-management messaging. The product competes in a low-cost generic category where manufacturing reliability and distribution economics are more important than traditional branded promotion.

What excipients are relevant to a THALITONE formulation strategy?

The current FDA-approved labeling should control any assessment of THALITONE’s inactive ingredients. Public product labeling identifies conventional tablet excipients rather than a novel delivery system. [1,2]

A commercially optimized chlorthalidone tablet would typically require the following functional excipient groups:

Formulation function	Candidate excipient class	Commercial objective
Dilution and dose uniformity	Microcrystalline cellulose, lactose or an alternative filler	Maintain blend uniformity, especially at 15 mg
Binder	Povidone or comparable dry binder	Improve granule or tablet strength
Disintegrant	Sodium starch glycolate, crospovidone or croscarmellose sodium	Support rapid tablet breakup
Lubricant	Magnesium stearate or lower-impact lubricant	Control ejection force without slowing dissolution
Glidant	Colloidal silicon dioxide	Improve powder flow and die filling
Taste and handling	Film coat or polishing system	Improve swallowability, appearance and moisture protection
Color	Approved pigment system	Support strength differentiation and product identification

The principal technical problem is not solubility. It is low-dose content uniformity. At 15 mg, chlorthalidone represents a smaller fraction of tablet mass than the excipient system. Segregation, electrostatic charging, lubricant overmixing and poor die filling can produce unacceptable potency variation.

Which excipient risks matter most at the 15 mg strength?

The 15 mg tablet should receive the greatest development attention. A formulation that performs adequately at 50 mg may not maintain equivalent blend uniformity at 15 mg.

Key risks include:

1. Segregation between chlorthalidone and larger filler particles.
2. Overlubrication caused by excessive magnesium stearate mixing.
3. Slow dissolution after increasing compression force.
4. Tablet weight variability during high-speed compression.
5. Moisture uptake affecting flow, hardness or disintegration.
6. Patient intolerance associated with lactose or other excipients.
7. Cross-contamination in multiproduct manufacturing facilities.

A practical development path is low-shear premixing of chlorthalidone with a portion of the filler, followed by controlled geometric dilution. Process analytical technology can monitor blend uniformity, feeder performance, tablet weight and near-infrared content signals. The strategy should target robust performance across commercial equipment rather than a narrow laboratory operating window.

What formulation patents protect THALITONE?

THALITONE’s principal commercial asset is not a newly patented molecular entity or advanced delivery system. Chlorthalidone has been used clinically for decades, and the active ingredient is generally treated as an off-patent compound.

The likely protection profile is therefore:

Protection category	Strategic relevance
Chlorthalidone compound patent	No meaningful current barrier expected
Basic immediate-release tablet	Usually difficult to protect broadly
15 mg strength	Potential product differentiation, but dose strength alone is generally weak patent subject matter
Manufacturing process	Possible protection if a process has non-obvious control features
Excipient composition	Possible only if the composition produces a demonstrated technical effect
Method of treatment	Potentially relevant, but vulnerable to prior-art and obviousness challenges
Trade dress and branding	Commercial protection, not patent exclusivity
Regulatory exclusivity	Not expected to provide a material current barrier for an established product

A new patent position would need to claim more than the presence of chlorthalidone in a conventional tablet. Stronger candidates could include a validated low-dose composition with unusually narrow dissolution performance, improved content uniformity, reduced hygroscopicity, a defined particle-size distribution or a manufacturing process that solves a documented scale-up problem.

A formulation patent would face substantial prior-art pressure because conventional fillers, binders, disintegrants and lubricants are widely used in oral tablets. The patent case would be stronger if the applicant could demonstrate an unexpected result, such as materially improved 15 mg content uniformity or dissolution stability under accelerated storage.

When does THALITONE lose exclusivity?

THALITONE does not appear to depend on a current new-chemical-entity exclusivity period. Its commercial protection is primarily regulatory and market-based rather than patent-based.

The relevant exclusivity analysis is:

Exclusivity type	THALITONE assessment
New chemical entity exclusivity	Not applicable to an established chlorthalidone product
Orphan-drug exclusivity	Not applicable based on the product’s conventional hypertension and edema use
Pediatric exclusivity	No material current barrier identified
New formulation exclusivity	Requires a separately approved qualifying product
Method-of-use exclusivity	Requires an Orange Book-listed protected use
Patent exclusivity	No established broad current barrier for chlorthalidone as an active ingredient
Generic competition	Legally and technically feasible, subject to FDA requirements

The absence of strong active-ingredient exclusivity means that an applicant can pursue generic or authorized-generic strategies without licensing a proprietary compound. The principal regulatory route for a generic tablet is an abbreviated new drug application demonstrating pharmaceutical equivalence and bioequivalence to the relevant reference product. [3]

What is the Orange Book status of THALITONE?

The Orange Book determines whether an NDA product has listed patents or exclusivity that could affect an ANDA applicant. Orange Book entries can change, and the relevant product, strength and reference-listed-drug designation must be checked against the current FDA database. [4]

For commercial planning, the important questions are:

• Whether THALITONE is the reference listed drug for the targeted strength.
• Whether the 15 mg strength has an active approved ANDA competitor.
• Whether any patents are listed against the product.
• Whether a listed method-of-use patent is relevant to the proposed label.
• Whether a Paragraph IV certification would be required.
• Whether a section viii statement could avoid a patented use.

Because chlorthalidone is an established molecule, a Paragraph IV challenge would be more likely to target a listed formulation or use patent than the active ingredient itself. If no relevant patent is listed, an ANDA applicant would generally face a conventional approval pathway rather than patent litigation.

Which companies are likely to challenge THALITONE?

The competitive field consists primarily of generic manufacturers with existing oral-solid-dose infrastructure. Likely participants include companies that already manufacture antihypertensive tablets, have access to chlorthalidone API and can support low-volume products economically.

The most credible competitor profiles are:

Large generic manufacturers

These companies can absorb development and validation costs across multiple strengths. Their advantages include established FDA operations, procurement scale and broad pharmacy distribution. Their disadvantage is lower interest in a small product unless the 15 mg strength has favorable reimbursement or limited competition.

Specialty generic manufacturers

A specialty manufacturer can target the 15 mg niche, supply shortages or institutional buyers. It may compete through flexible batch sizes and lower overhead rather than broad portfolio scale.

Authorized-generic suppliers

An authorized generic can use the branded product’s formulation or manufacturing platform, depending on the commercial arrangement. This structure can protect channel share while lowering acquisition cost for payers and wholesalers.

Contract development and manufacturing organizations

A CDMO could create value by offering a validated, multi-strength chlorthalidone platform with blend-uniformity controls and a ready-to-file CMC package. The opportunity is stronger if the CDMO can manufacture other low-dose antihypertensive products on the same line.

What generic entry risks exist for THALITONE?

Generic entry risk is high at the active-ingredient level and moderate at the product-platform level.

Risk	Impact
Off-patent chlorthalidone	High
Conventional tablet technology	High
Availability of common excipients	Low barrier
Low-dose content uniformity	Moderate technical barrier
Three-strength manufacturing	Moderate operational barrier
Limited market size	May deter entry
Brand recognition	Provides some commercial retention
Payer substitution	High pressure on brand price
Supply shortages	Can create temporary opportunity

A generic applicant must show equivalence in dosage form, strength, route of administration and performance. FDA product-specific guidance, where available, can influence dissolution testing, bioequivalence design and CMC expectations. [3,5]

The most defensible commercial position is not simply "generic chlorthalidone." It is a dependable 15 mg, 25 mg and 50 mg supply program with consistent dissolution, stable packaging and broad wholesaler access.

What excipient opportunities could create commercial differentiation?

Lactose-free or low-allergen tablet

A lactose-free formulation could address patients with lactose intolerance and institutional buyers seeking simplified excipient profiles. The opportunity is commercially limited unless labeling, reimbursement or procurement systems reward the distinction.

Moisture-protective formulation

A moisture-controlled formulation could improve shelf-life robustness and reduce tablet softening or dissolution drift. High-barrier blister packaging, desiccant systems and a low-moisture manufacturing process may be more economical than a complex excipient change.

Improved low-dose uniformity

This is the strongest technical opportunity. A formulation designed around ordered mixing, controlled particle-size distribution or granulation could produce a measurable advantage at 15 mg. The advantage must be demonstrated with process capability data and stability results.

Smaller tablet platform

A smaller tablet can improve swallowability, but reducing tablet mass may worsen content uniformity. The design should prioritize dose accuracy before tablet-size reduction.

Color-coded strength system

Distinct visual identification for 15 mg, 25 mg and 50 mg can reduce dispensing errors. This is a packaging and human-factors opportunity rather than a high-value patent position.

Scored tablet

A score may support dose flexibility but creates risks involving split-tablet uniformity, friability and labeling. A scored design should be supported by split-tablet testing under applicable FDA and pharmacopeial standards.

How does THALITONE compare with hydrochlorothiazide and indapamide?

Factor	Chlorthalidone	Hydrochlorothiazide	Indapamide
Duration	Long	Shorter	Intermediate to long
Dose flexibility	Strong opportunity at 15 mg	Broad generic availability	Often positioned as a low-dose product
Generic competition	High	Very high	High
Excipient differentiation	Low-dose uniformity and tolerability	Cost and broad supply	Modified-release or low-dose positioning in some products
Commercial barrier	Limited patent protection	Limited patent protection	Product-specific formulation differences
Key clinical perception	Durable blood-pressure control	Familiar, inexpensive diuretic	Alternative thiazide-like option

THALITONE’s commercial case depends on maintaining access to a long-acting chlorthalidone product. It is vulnerable to substitution by inexpensive hydrochlorothiazide, but it can retain demand where clinicians prefer chlorthalidone’s duration and established use.

What manufacturing and IP barriers affect commercialization?

The main manufacturing barriers are operational:

• Reliable low-dose blending.
• API particle-size control.
• Prevention of segregation during transfer.
• Tablet weight and hardness consistency.
• Dissolution control across strengths.
• Cleaning validation for a potent, low-dose active.
• Supplier qualification for chlorthalidone API.
• Stability under ordinary distribution conditions.

The main intellectual-property barrier is weak broad patentability. A new entrant should not rely on a conventional excipient list as its primary moat. Better assets include:

1. A validated low-dose manufacturing process.
2. A proprietary API particle-engineering method.
3. A technically supported excipient composition.
4. A supply agreement with qualified API and packaging vendors.
5. A regulatory dossier covering multiple strengths.
6. A branded-generic distribution strategy.

What licensing deals and settlement agreements affect THALITONE?

No major current licensing or settlement structure is necessary to commercialize ordinary chlorthalidone tablets if the product is developed independently and no enforceable listed patent blocks the proposed label.

A licensing deal could still have value in four areas:

• Access to the existing THALITONE brand and distribution network.
• Use of a validated formulation and CMC package.
• Authorized-generic commercialization.
• Acquisition of supply rights for a differentiated 15 mg product.

A settlement agreement would become relevant only if an ANDA applicant faced an active patent claim. In the absence of a material listed patent, the commercial decision is more likely to turn on launch economics, manufacturing capacity and payer contracting than on patent settlement timing.

What is the revenue opportunity for THALITONE?

Revenue exposure is constrained by generic pricing and the mature hypertension market. The product can still generate commercial value through:

• Higher-value 15 mg availability.
• Reduced stockouts.
• Institutional and mail-order supply.
• Authorized-generic arrangements.
• Multi-strength contracting.
• Regional distribution where generic supply is inconsistent.
• Combination-product development using chlorthalidone as the diuretic component.

A branded product must justify its price through supply continuity, differentiated strength availability, quality performance or channel access. A generic entrant should model rapid price compression after approval, with greater resilience if it is one of few suppliers of the 15 mg strength.

Key Takeaways

• THALITONE is a chlorthalidone immediate-release tablet product with 15 mg, 25 mg and 50 mg strengths.
• Chlorthalidone is an established off-patent active ingredient; exclusivity is not the central commercial moat.
• The strongest formulation opportunity is accurate and reproducible 15 mg content uniformity.
• Conventional excipients are unlikely to support broad patent protection without unexpected technical results.
• Generic entry risk is high, although limited market size and manufacturing complexity may reduce the number of entrants.
• A lactose-free, moisture-robust or smaller tablet may create commercial differentiation, but these features require evidence of patient or manufacturing value.
• The most defensible strategy combines multi-strength manufacturing, stable supply, disciplined CMC execution and targeted distribution.
• Orange Book status, listed patents and reference-listed-drug designations should be reviewed before filing or launch planning.

FAQs

Is THALITONE a biologic or biosimilar product?

No. THALITONE is a small-molecule chlorthalidone tablet. Biosimilar regulation does not apply.

Can a generic manufacturer launch 15 mg chlorthalidone?

Yes, subject to FDA approval, pharmaceutical equivalence, bioequivalence, CMC validation and any applicable patent or exclusivity requirements.

Is the 15 mg THALITONE strength commercially defensible?

It can be more defensible than the 25 mg and 50 mg strengths because low-dose manufacturing and content uniformity create greater technical demands. The advantage is operational rather than automatically patent-based.

Can a new excipient composition obtain a patent for chlorthalidone?

Yes, but a conventional combination of filler, binder, disintegrant and lubricant would face substantial obviousness risk. Patent strength improves when the composition produces a documented, unexpected technical result.

What is the best commercial strategy for a THALITONE generic?

The strongest strategy is a three-strength platform centered on reliable 15 mg production, validated blend uniformity, stable packaging, competitive cost and early wholesaler or institutional contracting.

References

1. U.S. Food and Drug Administration. (n.d.). THALITONE (chlorthalidone) tablets: Prescribing information.
2. National Library of Medicine. (n.d.). DailyMed: THALITONE - chlorthalidone tablet.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Guidance for industry.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations.
5. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development.